Provided by Tiger Fintech (Singapore) Pte. Ltd.

Guardant Health Inc.

41.14
-0.5200-1.25%
Volume:512.36K
Turnover:21.11M
Market Cap:5.10B
PE:-12.18
High:42.40
Open:41.74
Low:40.57
Close:41.66
Loading ...

GH Research: Promising Clinical Results and Strong Financial Position Justify Buy Rating

TIPRANKS
·
10 May

GH Research Is Maintained at Buy by Guggenheim

Dow Jones
·
10 May

GH Research Price Target Maintained With a $40.00/Share by HC Wainwright & Co.

Dow Jones
·
09 May

Psychedelic: Compass, GH Research, MindMed report quarterly earnings

TIPRANKS
·
08 May

GH Research Q1 EPS $(0.19) Beats $(0.39) Estimate

Benzinga
·
08 May

Guardant Health Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

THOMSON REUTERS
·
08 May

Cathie Wood’s ARK Investment buys 237.4K shares of Guardant Health today

TIPRANKS
·
07 May

Guardant Health Is Maintained at Overweight by Piper Sandler

Dow Jones
·
07 May

AmirAli Talasaz, Co-CEO of Guardant Health Inc., Reports Disposal of Common Shares

Reuters
·
06 May

Guardant Health price target raised to $57 from $52 at Scotiabank

TIPRANKS
·
05 May

Guardant Health Is Maintained at Sector Outperform by Scotiabank

Dow Jones
·
05 May

S&P 500 Futures Drop In Premarket Trading; AngloGold Ashanti, Henry Schein Lead

Dow Jones
·
05 May

Guardant Health Inc : Scotiabank Raises Target Price to $57 From $52

THOMSON REUTERS
·
05 May

Stock Track | Guardant Health Soars 5.14% in Pre-Market on Strong Q1 Results and Analyst Upgrade

Stock Track
·
02 May

Morgan Stanley Raises Price Target on Guardant Health to $60 From $52, Keeps Overweight Rating

MT Newswires Live
·
02 May

Guardant Health First Quarter 2025 Earnings: Beats Expectations

Simply Wall St.
·
02 May

Analysts Offer Insights on Healthcare Companies: Guardant Health (GH), Humana (HUM) and Evolus (EOLS)

TIPRANKS
·
02 May

H.C. Wainwright Remains a Buy on GH Research (GHRS)

TIPRANKS
·
01 May

UBS Adjusts Guardant Health Price Target to $70 From $65, Maintains Buy Rating

MT Newswires Live
·
01 May

Guardant Health Is Maintained at Buy by UBS

Dow Jones
·
01 May